# Trade Mark Journal No.2025/052 26 December 2025

## UK00004281590 21 October 2025 (5,40,42,44)

International priority date claimed: 8 May 2025 (United States of America) (99175604)

Class 5
  Therapeutic pharmaceuticals in the nature of oligonucleotide-conjugate based therapies, oligonucleotide-antibody conjugate based therapies, and oligonucleotide-antibody fragment conjugate based therapies for the treatment of and prevention of musculoskeletal, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, and muscle atrophy related diseases and disorders; pharmaceutical preparations for the treatment and prevention of viral, metabolic, endocrine, musculoskeletal, autoimmune, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, neurodegenerative, gastrointestinal, hormonal, dermatological, psychiatric, genetic, and immune system related diseases and disorders; pharmaceutical preparations for the treatment and prevention of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; therapeutic pharmaceutical for the treatment and prevention of viral, metabolic, endocrine, musculoskeletal, autoimmune, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, neurodegenerative, gastrointestinal, hormonal, dermatological, psychiatric, genetic, and immune system related diseases and disorders; therapeutic pharmaceuticals for the treatment and prevention of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes.
Class 40
  Custom manufacturing of oligonucleotide-conjugate based pharmaceutical therapies, oligonucleotide-antibody conjugate based pharmaceutical therapies, and oligonucleotide-antibody fragment conjugate based pharmaceutical therapies; custom manufacturing of pharmaceuticals; contract manufacturing in the field of pharmaceuticals.
Class 42
  Medical and scientific research, namely, conducting clinical trials for others; providing medical and scientific research information in the fields of pharmaceuticals, biotechnology, and clinical trials; pharmaceutical research and development; pharmaceutical products development; research and development in the field of biotechnology; providing medical and scientific research information in the fields of pharmaceuticals, therapeutics, medicines and vaccines; providing technical information in the field of pharmaceutical manufacturing; online medical information services, namely, providing a website related to healthcare, health awareness, diseases, disorders, treatment options, and the diagnostic, prophylactic and therapeutic properties of medicines and vaccines.
Class 44
  Providing information relating to the diagnostic, prophylactic and therapeutic properties of pharmaceuticals, therapeutics, medicines, and vaccines, and medical information in the fields of healthcare, health conditions, health awareness and treatment options; medical information services, namely, providing information related to healthcare, diseases, disorders, and treatment options.

Avidity Biosciences, Inc.

Representative: Abion UK Limited